Targeting Metabolic Heterogeneity in the Tumor Microenvironment: From Metabolic Plasticity to Therapeutic Vulnerability

Metabolic heterogeneity has emerged as a defining feature of cancer, yet its origins and therapeutic implications are often considered in a cancer cell-centric manner. Here, we summarize evidence that metabolic diversity is instead dynamically co-regulated by cancer cells, stromal and immune compartments, and by the abnormal vasculature within the tumor microenvironment (TME). We discuss how spatial and temporal fluctuations in oxygen and nutrient availability generate distinct metabolic niches that select for phenotypic plasticity and adaptive cell states. Across these niches, cancer cells differentially engage glycolysis, oxidative phosphorylation (OXPHOS), glutamine and lipid metabolism, and stress-response pathways, generating metabolic states associated with proliferation, survival, metastatic capacity, and therapy resistance. Particular attention is given to tumor endothelial cells (TECs), whose metabolic states influence vascular function and nutrient distribution and may thereby contribute to intratumoral metabolic heterogeneity. In parallel, oncogenic mutations, tissue context, and treatment-induced stress remodel pathway usage and foster the emergence of metabolically adaptable, stem-like, and drug-tolerant populations. Thus, cancer metabolic heterogeneity is shaped by cellular and environmental crosstalk rather than as a static consequence of genetic variation alone. This framework has important translational implications: effective metabolic therapies will require context-aware strategies that target specific niche liabilities while accounting for vascular state, immune function, and adaptive rewiring. Defining when and where these metabolic states create selective dependencies will be essential for translating metabolic heterogeneity into therapeutically actionable vulnerabilities.

Authors

Publication Details

Journal
Cancer Biome and Targeted Therapy
Published
2026-11-14
DOI
https://doi.org/10.66505/cbtt.v1i4.44
Primary Topic
Cancer, Hypoxia, and Metabolism
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Targeting Metabolic Heterogeneity in the Tumor Microenvironment: From Metabolic Plasticity to Therapeutic Vulnerability

Alina Errerd, Anna Rita Cantelmo, Louay Bettaieb, Evan Courmont et al.
Cancer Biome and Targeted Therapy
Cancer, Hypoxia, and Metabolism
article

Targeting Metabolic Heterogeneity in the Tumor Microenvironment: From Metabolic Plasticity to Therapeutic Vulnerability

Alina Errerd, Anna Rita Cantelmo, Louay Bettaieb, Evan Courmont, Corina Birzoi
article en

Abstract

Metabolic heterogeneity has emerged as a defining feature of cancer, yet its origins and therapeutic implications are often considered in a cancer cell-centric manner. Here, we summarize evidence that metabolic diversity is instead dynamically co-regulated by cancer cells, stromal and immune compartments, and by the abnormal vasculature within the tumor microenvironment (TME). We discuss how spatial and temporal fluctuations in oxygen and nutrient availability generate distinct metabolic niches that select for phenotypic plasticity and adaptive cell states. Across these niches, cancer cells differentially engage glycolysis, oxidative phosphorylation (OXPHOS), glutamine and lipid metabolism, and stress-response pathways, generating metabolic states associated with proliferation, survival, metastatic capacity, and therapy resistance. Particular attention is given to tumor endothelial cells (TECs), whose metabolic states influence vascular function and nutrient distribution and may thereby contribute to intratumoral metabolic heterogeneity. In parallel, oncogenic mutations, tissue context, and treatment-induced stress remodel pathway usage and foster the emergence of metabolically adaptable, stem-like, and drug-tolerant populations. Thus, cancer metabolic heterogeneity is shaped by cellular and environmental crosstalk rather than as a static consequence of genetic variation alone. This framework has important translational implications: effective metabolic therapies will require context-aware strategies that target specific niche liabilities while accounting for vascular state, immune function, and adaptive rewiring. Defining when and where these metabolic states create selective dependencies will be essential for translating metabolic heterogeneity into therapeutically actionable vulnerabilities.

Cancer Biome and Targeted Therapy
Cancer, Hypoxia, and Metabolism
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon